1. Pomerantz LLP investigates potential securities fraud at Inovio Pharmaceuticals. 2. FDA accepted Inovio's BLA for INO-3107 but denied accelerated approval. 3. Inovio's stock dropped 24.45% after the FDA announcement. 4. Inovio plans to meet with the FDA about potential accelerated approval. 5. The company currently does not plan on standard review approval.
FAQ
Why Very Bearish?
The drop in stock price by over 24% indicates significant negative investor sentiment. Historical context shows similar FDA rejections lead to longer recovery periods for biotech stocks.
How important is it?
Developments regarding FDA applications and investigation have a high likelihood of affecting stock price. Market concerns about credibility can deter investment.
Why Short Term?
The immediate response to FDA news and ongoing investigations suggest urgent market reactions. Over the next few weeks, investors might further react based on developments from FDA meetings.
Investor Alert: Pomerantz Law Firm Investigates Inovio Pharmaceuticals (NASDAQ: INO)
NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP has launched an investigation into claims on behalf of investors of Inovio Pharmaceuticals, Inc. (NASDAQ: INO). The firm is assessing whether Inovio and certain of its officers and directors have engaged in securities fraud or other unlawful business practices. Investors who have concerns are encouraged to reach out to Danielle Peyton at newaction@pomlaw.com or call 646-581-9980, ext. 7980.
FDA's Response to Inovio's Application
On December 29, 2025, the U.S. Food and Drug Administration (FDA) announced its acceptance of Inovio’s Biologics License Application (BLA) for INO-3107, a proposed treatment for recurrent respiratory papillomatosis. Initially submitted under the accelerated approval pathway, the FDA indicated that Inovio had not provided sufficient data to support this expedited review.
Stock Price Decline
Following the FDA's announcement, Inovio’s share price experienced a significant decline, falling $0.56 per share or 24.45%, to close at $2.29 on the same day. This sharp drop highlights the market's reaction to the regulatory setbacks faced by the company.
Next Steps for Inovio
Inovio has stated that it currently does not intend to pursue approval under the standard review timeline. Instead, the company will request a meeting with the FDA to explore potential avenues for seeking accelerated approval in the future.
About Pomerantz LLP
Pomerantz LLP, with its offices located in major cities including New York, Chicago, and Los Angeles, is recognized as a leading firm in corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, the firm has a legacy of fighting for the rights of victims affected by securities fraud and corporate misconduct. Over its 85-year history, Pomerantz has recovered numerous multimillion-dollar damages on behalf of class members.
Contact Information
- Name: Danielle Peyton
- Firm: Pomerantz LLP
- Email: dpeyton@pomlaw.com
- Phone: 646-581-9980 ext. 7980
For more information regarding joining the class action, please click here.
Attorney advertising. Prior results do not guarantee similar outcomes.